Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CMPS
COMPASS Pathways Plc
stock NASDAQ ADR

At Close
Jul 22, 2026 3:59:55 PM EDT
11.93USD-2.053%(-0.25)1,723,913
10.36Bid   13.67Ask   3.31Spread
Pre-market
Jul 22, 2026 9:28:30 AM EDT
12.06USD-0.985%(-0.12)11,077
After-hours
Jul 22, 2026 4:48:30 PM EDT
11.93USD+0.006%(+0.00)108,451
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
04:35PM EST  Understanding The Psilocybin Supply Chain: Every Production Method Explained   Benzinga
Jan 24, 2022
09:15AM EST  Psyched: Eleusis To Go Public Via Merger, New Psychedelics Bills In Utah, Virginia, Kansas And Missouri   Benzinga
Jan 19, 2022
01:35PM EST  Two-Thirds Of Physicians Say Psilocybin Therapy Can Help Treatment-Resistant Depression, New Survey Shows   Benzinga
07:00AM EST  Two thirds of physicians surveyed believe psilocybin therapy has   GlobeNewswire Inc
Jan 10, 2022
08:53AM EST  Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington   Benzinga
Jan 4, 2022
02:36PM EST  Psilocybin Does Not Produce Adverse Effects On Cognition Or Emotional Function, New Study Finds   Benzinga
02:11PM EST  Understanding The Psilocybin Supply Chain: Every Production Method Explained   Benzinga
07:00AM EST  Study demonstrates feasibility of simultaneous administration of COMP360 psilocybinin a controlled setting to healthy participants with 1:1 therapist support   GlobeNewswire Inc
Jan 3, 2022
01:03PM EST  Understanding The Psilocybin Supply Chain: Every Production Method Explained   Benzinga
Dec 30, 2021
10:32AM EST  Compass Pathways Option Alert: May 20 $25 Calls at the Ask: 185 @ $3.0 vs 228 OI; Ref=$22.61   Benzinga
09:37AM EST  2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?   Benzinga
Dec 21, 2021
12:20PM EST  'Another Washington City Moves To Decriminalize Psychedelics, With Unanimous Council Vote' -Marijuana Moment Report   Benzinga
11:03AM EST  'GOP Lawmakers File Bills To Streamline Research Into Marijuana, Psychedelics And Other Schedule I Drugs: "One of the things we've done in the past is we've put things on Schedule I and then we've not researched it."' -Marijuana Moment   Benzinga
Dec 17, 2021
03:49PM EST  'Activists File Colorado Ballot Initiatives To Legalize Psychedelics And Establish 'Healing Center' Program' -Marijuana Moment Report   Benzinga
12:52PM EST  'Congressman Asks Colleagues To Demand DEA Allow Psilocybin Treatment For Terminal Patients' -Marijuana Moment Report   Benzinga
11:15AM EST  Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index   Benzinga
07:06AM EST  COMPASS Pathways To Be Added To NASDAQ Biotech Index, Effective Dec. 20, 2021   Benzinga
07:00AM EST  COMPASS Selected for Addition to NASDAQ Biotechnology Index   GlobeNewswire Inc
Dec 16, 2021
07:40AM EST  Matthew Owensappointed General Counseland Chief Legal Officer;   GlobeNewswire Inc
Dec 13, 2021
09:57AM EST  Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms   Benzinga
07:10AM EST  COMPASS Pathways Announces Outcome Of 25Mg COMP360 Psilocybin Therapy As Adjunct To SSRI Antidepressants In Open-label Treatment-resistant Depression Study   Benzinga
07:00AM EST  -- Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASSs phase IIb trial -- All patients tolerated COMP360 psilocybin therapy well   GlobeNewswire Inc
Dec 6, 2021
04:39PM EST  Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways   Benzinga
11:19AM EST  'DEA Backs White House Plan To Streamline Research On Marijuana, Psychedelics And Other Schedule I Drugs' -Marijuana Moment Report   Benzinga
Dec 3, 2021
03:28PM EST  New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers   Benzinga
07:03AM EST  COMPASS Pathways Names Michael Falvey CFO   Benzinga
07:00AM EST  Michael Falvey joins COMPASS Pathways as Chief Financial Officer   GlobeNewswire Inc
Dec 2, 2021
09:09AM EST  'DEA Again Boosts 2022 Production Goals For Psychedelics Like Psilocybin, MDMA and DMT' -Marijuana Moment Report   Benzinga
Dec 1, 2021
01:07PM EST  COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction   Benzinga
07:25AM EST  Compass Pathways Announces Results From Phase IIb Trial Of Investigational COMP360 Psilocybin Therapy For Treatment-resistant Depression   Benzinga
07:00AM EST  COMPASS Pathways announces further positive results from   GlobeNewswire Inc
Nov 30, 2021
04:15PM EST  Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways   Benzinga
Nov 24, 2021
09:06AM EST  'Former GOP Texas Governor Promotes Psychedelics Research For Veterans At Event With Leading Experts' -Marijuana Moment Report   Benzinga
Nov 23, 2021
07:00AM EST  COMPASS Pathways granted fifth US patent for crystalline psilocybin   GlobeNewswire Inc
Nov 22, 2021
12:13PM EST  Why We're Excited About Compass Pathways' Clinical Trial Treating PTSD With Psilocybin   Benzinga
07:30AM EST  10 Biggest Price Target Changes For Monday   Benzinga
06:27AM EST  HC Wainwright & Co. Maintains Buy on Compass Pathways, Raises Price Target to $120   Benzinga
Nov 9, 2021
01:49PM EST  '$CMPS Largest psilocybin trial finds the psychedelic is effective in treating serious depression...' -Tweet From STAT News' Adam Feuerstein   Benzinga
11:33AM EST  Compass Pathways Q3 EPS $(0.38) Up From $(1.30) YoY   Benzinga
11:31AM EST  COMPASS Announces Topline Results From Phase IIb Trial Of COMP360; Says Trial Achieved Primary Endpoint   Benzinga
10:36AM EST  Shares of COMPASS Pathways plc (CMPS) tanked over 25% on Tuesday morning despite the company reporting positive results from a mid-stage trial of its COMP360 psilocybin therapy for treatment-resistant depression.   RTTNews
07:19AM EST  COMPASS Pathways plc announces financial results and business   GlobeNewswire Inc
07:00AM EST  Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support   GlobeNewswire Inc
Nov 8, 2021
10:52AM EST  Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval   Benzinga
Nov 4, 2021
12:54PM EDT  This Psychedelics Unicorn's Stock Is Up 50% In One MonthBeating Bitcoin, Ethereum And Dogecoin   Benzinga
Nov 3, 2021
09:16AM EDT  COMPASS Pathways To Launch Phase 2 Trial Of COMP360 Psilocybin Therapy For Post-Traumatic Stress Disorder   Benzinga
08:00AM EDT  COMPASS Pathways to launch phase II trial of COMP360 psilocybin   GlobeNewswire Inc
Oct 29, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021   Benzinga
04:53AM EDT  Oppenheimer Initiates Coverage On Compass Pathways with Outperform Rating, Announces Price Target of $50   Benzinga
Oct 26, 2021
01:49PM EDT  Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent   Benzinga
Oct 21, 2021
12:11PM EDT  Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race   Benzinga
12:10PM EDT  Psychedelic Unicorn Compass Pathways Receives New Patent Approval   Benzinga
Oct 20, 2021
09:28AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Oct. 20, 2021: TSLA, TLRY, MNMD, BBIG, SDIG   Benzinga
09:01AM EDT  Compass Pathways Highlights Open-Label Study Of COMP360 Psilocybin Therapy For Depression In Cancer Patients; Says Study Demonstrates Feasibility Of Simultaneous Psilocybin Administration In Small Groups   Benzinga
09:00AM EDT  Investigator-initiated study shows remission in major depression symptoms for 50% of participants   GlobeNewswire Inc
Oct 19, 2021
07:12AM EDT  COMPASS Pathways Granted US Patent For Crystalline Psilocybin   Benzinga
07:00AM EDT  COMPASS Pathways is granted new US patent for crystalline psilocybin   GlobeNewswire Inc
Oct 18, 2021
01:37PM EDT  Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation   Benzinga
Oct 14, 2021
12:38PM EDT  Compass Pathways Option Alert: Dec 17 $60 Calls at the Ask: 1816 @ $2.8 vs 622 OI; Earnings 11/11 Before Open [est] Ref=$31.8999   Benzinga
Oct 13, 2021
04:25PM EDT  There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are   Benzinga
03:41PM EDT  Compass Pathways Option Alert: Jan 21 $65 Calls Sweep (15) above Ask!: 145 @ $2.854 vs 769 OI; Earnings 11/11 Before Open [est] Ref=$31.36   Benzinga
Oct 8, 2021
04:20PM EDT  COMPASS Pathways Filing Shows Registration For Mixed Securities Shelf Offering, No Size Disclosed   Benzinga
Oct 5, 2021
05:09PM EDT  'POLITICSVA Is 'Very Closely' Following Psychedelics Research For Veterans With PTSD, Official Tells Lawmakers' -Marijuana Moment Report   Benzinga
Sep 22, 2021
11:51AM EDT  Is Ketamine A Psychedelic? Depends On Who You Ask   Benzinga
Sep 20, 2021
12:51PM EDT  Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial   Benzinga
09:16AM EDT  'Italian Referendum To Decriminalize Marijuana, Psilocybin And Other Drug Plants Gets Half A Million Signatures' -Marijuana Moment   Benzinga
Sep 17, 2021
09:49AM EDT  'Seattle Councilmember Says He'll Introduce Psychedelics Decriminalization Measure By Year's End' -Marijuana Moment Report   Benzinga
Sep 15, 2021
03:40PM EDT  Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0   Benzinga
Sep 14, 2021
12:54PM EDT  Meet The Top 12 CEOs In The Psychedelics Industry   Benzinga
07:00AM EDT  COMPASS Pathways acquires IP portfolio of novel psychedelic   GlobeNewswire Inc
Sep 13, 2021
12:48PM EDT  Meet The Top 12 CEOs In The Psychedelics Industry   Benzinga
Sep 10, 2021
07:00AM EDT  Hamilton Morris joins COMPASS Pathways to research new psychedelic   GlobeNewswire Inc
Sep 9, 2021
04:46PM EDT  Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?   Benzinga
Sep 3, 2021
12:00PM EDT  'Possessing And Cultivating Psychedelics Would Be Legalized In Michigan Under New Senate Bill' -Marijuana Moment   Benzinga
Sep 2, 2021
12:48PM EDT  'California Psilocybin Legalization Initiative Would Save State Millions In Enforcement Costs, Official Analysis Says' -Marijuana Moment Report   Benzinga
Aug 27, 2021
12:52PM EDT  Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression   Benzinga
Aug 12, 2021
06:59AM EDT  Atai Life Sciences To Research Potent Psychedelic Herb Salvia Divinorum Through Its New Subsidiary   Benzinga
Aug 11, 2021
02:56PM EDT  What Do You Really Know About Psychedelics And Psychedelics Stocks?   Benzinga
09:06AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
07:28AM EDT  Compass Pathways Q2 EPS $(0.44) Misses $(0.35) Estimate   Benzinga
07:00AM EDT  COMPASS Pathways plc announces financial results and business   GlobeNewswire Inc
04:27AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
Aug 9, 2021
08:26PM EDT  Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies   Benzinga
Aug 5, 2021
02:51PM EDT  Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know   Benzinga
Aug 3, 2021
02:25PM EDT  Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies   Benzinga
Jul 29, 2021
08:33AM EDT  COMPASS Pathways Names Guy Goodwin As CMO   Benzinga
08:30AM EDT  Guy Goodwin joins COMPASS Pathways as Chief Medical Officer   GlobeNewswire Inc
Jul 27, 2021
12:10PM EDT  'Massachusetts Lawmakers Discuss Bill To Create Psychedelics Legalization Task Force At Hearing' -Marijuana Moment Report   Benzinga
Jul 23, 2021
06:10PM EDT  Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To 'Psychedelics Renaissance'   Benzinga
05:04PM EDT  Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance"   Benzinga
Jul 21, 2021
07:00AM EDT  Danielle Schlosser joins COMPASS Pathways from Verily Life   GlobeNewswire Inc
Jul 13, 2021
10:13AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021   Benzinga
08:49AM EDT  Citigroup Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $67   Benzinga
Jul 7, 2021
01:51PM EDT  Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies   Benzinga
Jul 5, 2021
06:00AM EDT  COMPASS Pathways joins forces with Kings College   GlobeNewswire Inc
Jul 3, 2021
12:32PM EDT  Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies   Benzinga
Jun 30, 2021
06:14PM EDT  Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More   Benzinga
07:00AM EDT  COMPASS Pathways launches new podcast Everyone   GlobeNewswire Inc
Jun 29, 2021
03:21PM EDT  Compass Pathways Completes Target Administration Of Psilocybin Therapy In World's Largest Study   Benzinga
Jun 28, 2021
10:21AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021   Benzinga
09:57AM EDT  UPDATE: Roth Capital On Compass Pathways Buy Rating: Key Findings Including 'Trends Of Better Cognitive Performance Compared With Baseline' Observed In COMP360 Groups By Week Four.   Benzinga
09:57AM EDT  UPDATE: Roth Capital On Compass Pathways Buy Rating: Firm Rests Rating On Phase 1 Results Of COMP360 Psilocybin Showing 'No Clinically-Relevant Negative Effect On Cognitive Function'.   Benzinga
09:56AM EDT  CMPS: Roth Capital Reiterates Buy Rating On Compass Pathways, Price Target $79.   Benzinga
09:01AM EDT  Maxim Group Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $70   Benzinga
07:01AM EDT  COMPASS Pathways Completes COMP360 Psilocybin Therapy Administration For 216 Patients In Large-scale Phase IIb Psilocybin Therapy Trial For Treatment-resistant Depression   Benzinga
07:00AM EDT  COMPASS Pathways completes COMP360 psilocybin therapy   GlobeNewswire Inc
Jun 23, 2021
07:00AM EDT  Programme aims to support students from under-represented ethnic groups   GlobeNewswire Inc
Jun 21, 2021
10:22AM EDT  Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform   Benzinga
Jun 18, 2021
05:12PM EDT  Peter Thiel-Backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public   Benzinga
Jun 16, 2021
07:30AM EDT  The Science Behind Using Psychedelics To Treat   GlobeNewswire Inc
Jun 8, 2021
01:12PM EDT  What Do You Really Know About Psychedelics And Psychedelics Stocks?   Benzinga
Jun 7, 2021
06:51AM EDT  Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York   Benzinga
Jun 3, 2021
09:30AM EDT  COMPASS Pathways, Kings College London Publish Cognition Results From COMP360 Psilocybin Study In Healthy Volunteers   Benzinga
09:28AM EDT  COMPASS Pathways and Kings College London publish cognition   GlobeNewswire Inc
Jun 2, 2021
10:36AM EDT  Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week   Benzinga
May 28, 2021
09:53AM EDT  Meet PsyBio, A Company Producing Psilocybin From Genetically-Modified Bacteria   Benzinga
May 27, 2021
12:20PM EDT  BTIG Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $63   Benzinga
09:23AM EDT  Cannabis Countdown: Top 10 Marijuana and Psychedelics Industry News Stories of the Week   Benzinga
09:18AM EDT  Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week   Benzinga
May 24, 2021
04:56PM EDT  COMPASS Pathways 13D Filing From ATAI Life Sciences Shows 19.7% Stake In Co.   Benzinga
May 21, 2021
08:25AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Friday, May 21, 2021: PFPT, PIXY, MNMD, WAFU, ZS   Benzinga
May 17, 2021
09:02AM EDT  Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public   Benzinga
May 14, 2021
04:26PM EDT  Compass Releases Q1 Earnings: Strong Cash Position For Psilocybin R&D Efforts   Benzinga
May 13, 2021
07:13AM EDT  Compass Pathways Q1 EPS $(0.35) Beats $(0.47) Estimate   Benzinga
07:00AM EDT  COMPASS Pathways plc announces financial results and business   GlobeNewswire Inc
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 11, 2021
10:37AM EDT  Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week   Benzinga
10:07AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021   Benzinga
07:43AM EDT  Cantor Fitzgerald Initiates Coverage On Compass Pathways with Overweight Rating, Announces Price Target of $71   Benzinga
May 4, 2021
10:30AM EDT  Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week   Benzinga
Apr 27, 2021
05:23PM EDT  COMPASS Pathways Launches Proposed Public Offering of 4M ADSs   Benzinga
10:29AM EDT  Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week   Benzinga
10:25AM EDT  Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week   Benzinga
Apr 26, 2021
08:03AM EDT  Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading   Benzinga
07:58AM EDT  Psyched: MindMed and Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Gets Back To Trading   Benzinga
Apr 22, 2021
04:07PM EDT  Psychedelics Company Atai Life Sciences Files For Nasdaq Listing In Sector's Highly Anticipated IPO   Benzinga
Apr 20, 2021
10:31AM EDT  Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week, 4/20/2021   Benzinga
07:00AM EDT  The Power of the Platform in Psychedelic Medicine   GlobeNewswire Inc
Apr 19, 2021
05:50PM EDT  Psyched: California Psychedelics Bill Passes Second Committee, GH Research Closes $125M Series B, Study Shows Psilocybin Could Equal SSRI Results In Depression   Benzinga
Apr 15, 2021
12:59PM EDT  Compass Pathways shares were trading higher after the company issued Q3 sales guidance above analyst estimates.   Benzinga
07:49AM EDT  The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split   Benzinga
03:00AM EDT  New England Journal of Medicine publishes exploratory study   GlobeNewswire Inc
Apr 14, 2021
04:18PM EDT  Cimpress Sees Q3 2021 Revs $579M Vs $526.92M Est; Sees Adj. EBITDA Of $55M   Benzinga
Apr 9, 2021
07:00AM EDT  COMPASS Pathways plc to participate in 20th Annual Needham Virtual   GlobeNewswire Inc
Apr 6, 2021
08:55AM EDT  Is Silicon Valley Replacing Big Pharma In Neuroscience?   Benzinga
Apr 1, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2021   Benzinga
09:57AM EDT  Roth Capital Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $88   Benzinga
07:13AM EDT  COMPASS Pathways Appoints Wayne Riley To Its Board   RTTNews
07:01AM EDT  COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors   GlobeNewswire Inc
Mar 26, 2021
01:49PM EDT  Psyched: Compass' New Patents, Cure Extends DEA License, Andrew Yang Supports Psilocybin in NYC   Benzinga
Mar 23, 2021
08:04AM EDT  Compass Pathways Says Granted 2 U.S. Patents   Benzinga
08:00AM EDT  COMPASS Pathways granted two US patents   GlobeNewswire Inc
Mar 15, 2021
12:45PM EDT  Psyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY   Benzinga
Mar 9, 2021
09:16AM EST  Compass Pathways Q4 EPS $(0.52) Up From $(0.90) YoY   Benzinga
07:00AM EST  COMPASS Pathways plc announces financial results and business   GlobeNewswire Inc
Mar 8, 2021
10:04AM EST  Psyched: Atai Raises $157M, Silo Wellness Goes Public, Mydecine Completes Export Of 'Magic Mushrooms'   Benzinga
Feb 25, 2021
08:30AM EST  Psychedelic Stocks Poised to Resume the Upward Trend   GlobeNewswire Inc
Feb 11, 2021
10:33AM EST  The Horizons Psychedelic Stock Index ETF, As Told By Its Fund Manager   Benzinga
08:30AM EST  264 Million Reasons Psychedelic Stocks Have More Room to Grow   GlobeNewswire Inc
Feb 9, 2021
03:21PM EST  Psyched: Boston Suburbs Decriminalize Psilocybin, Delic Begins Psychedelic Treatments, Australia Denies Legalization   Benzinga
07:12AM EST  COMPASS Pathways Highlights Collaboration Withs with UC San Diego, School of Medicine And Medical College of Wisconsin   Benzinga
07:02AM EST  COMPASS Pathways expands its Discovery Centerthrough new collaborations with world-leading scientists   GlobeNewswire Inc
Feb 6, 2021
08:37AM EST  Psyched: Boston Suburbs Decriminalize Psilocybin, Delic Begins Psychedelic Treatments, Australia Denies Legalization   Benzinga
Feb 3, 2021
07:00AM EST  COMPASS Pathways announces publication in Frontiers in Psychiatryof paper on therapist training programme for psilocybin therapy   GlobeNewswire Inc
Jan 27, 2021
08:41AM EST  First Psychedelics ETF Debuts On NEO Exchange   Benzinga
Jan 16, 2021
09:38AM EST  Psyched: Compass Launches Center Of Excellence, Entheon Purchases HaluGen, Atai Buys Majority Stake In Recognify   Benzinga
Jan 8, 2021
07:47AM EST  COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care   GlobeNewswire Inc
Jan 6, 2021
07:30AM EST  COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor conferences during the week of 11 January 2021.   GlobeNewswire Inc
Jan 4, 2021
08:00AM EST  Four Top Psychedelic Stock Picks for 2021   GlobeNewswire Inc
Dec 29, 2020
11:16AM EST  Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week   Benzinga
11:02AM EST  Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week   Benzinga
Dec 28, 2020
09:04AM EST  2020 Was The Year of Psychedelics Here's Why   Benzinga
Dec 22, 2020
09:13AM EST  Have Psychedelics Become The Next Neuroscience Biotech Frontier?   Benzinga
Dec 21, 2020
08:00AM EST  The Next Leg in the Bull Market for Psychedelic Stocks   GlobeNewswire Inc
Dec 2, 2020
02:54PM EST  Understanding The Psilocybin Supply Chain: Every Production Method Explained   Benzinga
Nov 13, 2020
03:06PM EST  Canaccord On COMPASS Pathways Reiterates Buy Rating, $80 Price Target   Benzinga
Nov 12, 2020
11:32AM EST  Compass Pathways shares were trading lower after the company reported Q3 EPS results down from last year.   Benzinga
07:25AM EST  Compass Pathways Q3 EPS $(1.30) Down From $(0.73) YoY   Benzinga
07:02AM EST  COMPASS Pathways plc announces financial results for third quarter   GlobeNewswire Inc
04:18AM EST  Earnings Scheduled For November 12, 2020   Benzinga
Nov 9, 2020
07:00AM EST  COMPASS Pathways joins the Psychiatry Consortium in a   GlobeNewswire Inc
Nov 3, 2020
11:53PM EST  Election2020: The Oregonian Calls Measure 109 In Favor Of Legalizing Psilocybin   Benzinga
08:15AM EST  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Nov. 3, 2020 (Election Day Edition): DOMO, SBE, CVS, CMPS, TLRY   Benzinga
Nov 2, 2020
04:19PM EST  Psyched: St. Vincent OKs Psychedelics Program, Delic To Go Public, Field Trip Drug Update   Benzinga
Oct 26, 2020
07:00AM EDT  COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO   GlobeNewswire Inc
Oct 25, 2020
09:23AM EDT  Psyched: Cybin Raises CA$45M, Numinus Harvests Legal Mushrooms, Toadstool Enters Psychedelic Space   Benzinga
Oct 16, 2020
02:55AM EDT  UPDATE - Trends in Psychedelic Drugs Research and Four Stocks You   GlobeNewswire Inc
Oct 14, 2020
10:23AM EDT  Compass Pathways shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a price target of $65 per share.   Benzinga
10:01AM EDT  Benzinga's Top Upgrades, Downgrades For October 14, 2020   Benzinga
06:56AM EDT  HC Wainwright & Co. Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $65   Benzinga
Oct 13, 2020
10:25AM EDT  Canaccord Genuity Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $80   Benzinga
Oct 4, 2020
09:06AM EDT  The Week In Cannabis: Peltz's Departure, Earnings, Stocks Slightly Down   Benzinga
Sep 30, 2020
08:20AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Sept. 30, 2020: VLDR, CMPS, BYND, MYOV, AXTI   Benzinga
Sep 29, 2020
09:16AM EDT  Citron's Left Calls Compass Pathways 'An Interesting Stock,' Notes Stock Is A Play On Medicinal-Purpose Psilocybin Mushrooms, Notes Peter Thiel Is An Advisor   Benzinga
Sep 22, 2020
04:03PM EDT  COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters option to purchase additional American Depositary Shares   GlobeNewswire Inc
Sep 18, 2020
02:31PM EDT  Mid-Afternoon Market Update: Dow Tumbles 300 Points; COMPASS Pathways Shares Spike Higher   Benzinga
12:31PM EDT  COMPASS Pathways Shares Open For Trade At $23.40; IPO Priced At $17/Share   Benzinga
12:00PM EDT  Still Waiting On 2 IPOs For Today: Athira Pharma (ATHA), Last Indicated At $20 After Pricing At $17/Share; COMPASS Pathways (CMPS), Last Indicated At $28 After Pricing At $17/Share   Benzinga
11:45AM EDT  COMPASS Pathway Shares Indicated $28.10 On 267K Shares   Benzinga
10:49AM EDT  COMPASS Pathways Shares Indicating $28.22 On 182K Shares   Benzinga
09:27AM EDT  COMPASS Pathways Shares Expected To Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $17/ADS   Benzinga
Sep 17, 2020
10:57PM EDT  COMPASS Pathways Announces Pricing Of Upsized IPO Of 7.50 Mln ADSs At $17.00/ADS   RTTNews
10:40PM EDT  COMPASS Pathways announces pricing of upsized initial public offering   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC